knowledge -WSS

knowledge

author：entertainment 2025-08-11 07:58:32 - browse：748

Sutter Health Palo Alto Medical Foundation facilities. health tech coverage from STAT — Adobe

When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury missed out on some crucial details. They didn’t hear, for example, how its former finance chief said the system would make an extra $200 million per year by making insurers contract with all of its hospitals instead of just a few. Or how its former CEO said, “Related to the health plans, we force them to pay us more.”

That evidence was indeed relevant, and the judge erred by not allowing it to be presented during the month-long trial that concluded in March 2022, a U.S. appeals court wrote in its ruling on Tuesday. The Ninth Circuit panel overturned Sutter’s win in the class-action case alleging that Sutter used its market power to drive up health care costs across the region by more than $400 million. Tuesday’s decision means the case will likely get a second trial.

“Effectively, the appellate court said the jury was tainted,” said Matthew Cantor, lead counsel for the plaintiffs. “So the jury’s verdict is discarded.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Ozempic has benefits for kidney disease as well as diabetes

hotspot

entertainment

leisure time

WSS

Change Healthcare: What is it, why does its cyberattack matter?

Medicare Advantage enrollment grows 7.1% to 33.4 million people

A new drug could help frostbite victims avoid its ravages

Families look for replacement for GSK asthma drug Flovent

$1 billion proposal to grow Boston, Massachusetts biotech

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Microsoft's Peter Lee: Generative AI could help doctors be more human

Sports medicine is finally prioritizing gender equality

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

In age of alternative facts, a scholarly course on calling out crap

Measles policy set amid Florida outbreak alarms vaccine proponents

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A new approach to psychiatric drug development

Tori Bowie and the unacceptable rates of Black maternal death

New study raises questions about niacin and heart health

hotspot

Longer MASH drug regimen improved liver, Akero study finds

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Stem cell biologist probes earliest stages of human development

Biden's 'march

Abridge raises $150m as clinical notes automation market heats up

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

hotspot

entertainment

leisure time

hotspot